Accelr8 Announces Collaboration Agreement with Promega
News Oct 18, 2005
Accelr8 Technology Corporation has announced the signing of an agreement with Promega Corporation regarding Accelr8's proprietary OptiChem® surface chemistry for use in microarraying slides.
The agreement will allow for exploration of techniques in microarray research using Accelr8 and Promega technologies.
According to David Howson, Accelr8's president, “This agreement represents another event for Accelr8 in licensing out our technology components in the microarraying space.”
“We're gratified that Promega evaluated the alternatives and chose OptiChem because of its performance advantages,” said Howson.
“We are also pleased to be associated with Promega because of their well-deserved reputation for excellence.”
Accelr8's OptiChem coatings are designed to provide performance advantages that help to make OptiChem-coated slides an enabling component of next generation microarrays.
The ongoing revenues from licensing occur in parallel with Accelr8's primary business focus in developing the BACcelr8r™ rapid bacterial analysis system.
Scientists used a gene editing method called CRISPR/Cas9 to generate mice that faithfully mimic a fatal respiratory disorder in newborn infants that turns their lips and skin blue. The new laboratory model allowed researchers to pinpoint the ailment's cause and develop a potential and desperately needed nanoparticle-based treatment.READ MORE